Keen Vision Acquisition Aktie - KVAC

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Current Price

11,16

Gebot

10,74

Fragen

17,84

Volumen

831

11,14 Tagesbereich 11,16

10,40 52-Wochen-Bereich 11,16

Marktkapitalisierung

216,125M

Handelsende

11,15

Handelsbeginn

11,14

Letzte Trade

100

11.16

Letzter Handelszeitpunkt

Finanzvolumen

US$ 9.266

VWAP

11,15

Durchschnittliches Volumen (3 Mio.)

9.476

Ausgegebene Aktien

19.366.000

Dividendenrendite

Kurs-Gewinn-Verhältnis

148,60

Gewinn pro Aktie (EPS)

0,08

Erlöse

Nettogewinn

1,46M

Sektor

Blank Checks

Branche

Blank Checks

Hauptsitz

Road Town, Tortola, Vgb

Gegründet

Keen Vision Acquisition Corporation is listed in the Blank Checks sector of the NASDAQ with ticker KVAC. The last closing price for Keen Vision Acquisition was US$11,15. Over the last year, Keen Vision Acquisition shares have traded in a share price range of US$ 10,40 to US$ 11,16.

Keen Vision Acquisition currently has 19.366.000 shares in issue. The market capitalisation of Keen Vision Acquisition is US$215,93 million. Keen Vision Acquisition has a price to earnings ratio (PE ratio) of 148.60.

Medera’s Novoheart Expands Human Cardiac Research with CTScreen™ Installation at University Medical Center, Utrecht

Cutting-Edge Cardiac Research: Novoheart’s CTScreen™ system has been installed at UMC Utrecht, equipping...

Medera’s Novoheart and Curi Bio Partner to Transform Human-Based Cardiac Drug Screening

Innovative Technology Integration: The strategic partnership seamlessly integrates the unique ability of...

Medera’s Novoheart Releases Latest Cardiac Screening Innovation CTScreen v1.5 to Advance High-Throughput, Automated Human-Based Drug Testing

Innovation installed by AstraZeneca for advancing human heart-based R&D for investigational cardiovascular...

Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology

Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology PR...

Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection Fraction

Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating...

Medera Inc. to be Listed on NASDAQ Through a Merger Agreement with Keen Vision Acquisition Corporation

Medera Inc. to be Listed on NASDAQ Through a Merger Agreement with Keen Vision Acquisition Corporation PR Newswire SUMMIT, N.J. and BOSTON, Sept...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0.02	0.179533213645	11.14	11.16	11.09	2782	11.14003163	CS
4	0.06	0.540540540541	11.1	11.16	11.09	5225	11.11446031	CS
12	0.25	2.29147571036	10.91	11.16	10.91	9476	11.02315818	CS
26	0.47	4.3966323667	10.69	11.16	10.67	54016	10.76857369	CS
52	0.74	7.10172744722	10.42	11.16	10.4	54523	10.66386192	CS
156	0.96	9.41176470588	10.2	11.16	10.14	65065	10.50080437	CS
260	0.96	9.41176470588	10.2	11.16	10.14	65065	10.50080437	CS

KVAC - Frequently Asked Questions (FAQ)

What is the current Keen Vision Acquisition share price?

The current share price of Keen Vision Acquisition is US$ 11,16

How many Keen Vision Acquisition shares are in issue?

Keen Vision Acquisition has 19.366.000 shares in issue

What is the market cap of Keen Vision Acquisition?

The market capitalisation of Keen Vision Acquisition is USD 215,93M

What is the 1 year trading range for Keen Vision Acquisition share price?

Keen Vision Acquisition has traded in the range of US$ 10,40 to US$ 11,16 during the past year

What is the PE ratio of Keen Vision Acquisition?

The price to earnings ratio of Keen Vision Acquisition is 148,6

What is the reporting currency for Keen Vision Acquisition?

Keen Vision Acquisition reports financial results in USD

What is the latest annual profit for Keen Vision Acquisition?

The latest annual profit of Keen Vision Acquisition is USD 1,46M

What is the registered address of Keen Vision Acquisition?

The registered address for Keen Vision Acquisition is RITTER HOUSE, WICKHAMS CAY II, PO BOX 3170, ROAD TOWN, TORTOLA, VG1110

Which industry sector does Keen Vision Acquisition operate in?

Keen Vision Acquisition operates in the BLANK CHECKS sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
STAKSTAK Inc	US$ 3,97 (156,13%)	174,23k
ORGOOrganogenesis Holdings Inc	US$ 6,21 (102,28%)	59M
TRNRInteractive Strength Inc	US$ 2,57 (67,97%)	193,57M
PMAXPowell Max Ltd	US$ 0,511 (43,54%)	137,18M
ARBBARB IOT Group Ltd	US$ 0,6635 (38,23%)	59,08M
NVNINVNI Group Ltd	US$ 0,99 (-50,50%)	72,28M
SPGCSacks Parente Golf Inc	US$ 0,2085 (-48,65%)	57,4M
ADGMAdagio Medical Holdings Inc	US$ 0,8081 (-47,53%)	756,64k
PRAXPraxis Precision Medicines Inc	US$ 38,60 (-40,64%)	3,17M
SAGSAG Holdings Ltd	US$ 1,19 (-38,97%)	788,89k
NVDANVIDIA Corporation	US$ 124,92 (3,97%)	379,97M
TRNRInteractive Strength Inc	US$ 2,57 (67,97%)	192,48M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	US$ 13,44 (7,78%)	153,64M
PMAXPowell Max Ltd	US$ 0,511 (43,54%)	136,35M
LCIDLucid Group Inc	US$ 2,22 (-0,45%)	134,28M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Keen Vision Acquisition Corporation (KVAC)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Über Keen Vision Acquisition Corporation

KVAC Neueste Nachrichten

Medera’s Novoheart Expands Human Cardiac Research with CTScreen™ Installation at University Medical Center, Utrecht

Medera’s Novoheart and Curi Bio Partner to Transform Human-Based Cardiac Drug Screening

Medera’s Novoheart Releases Latest Cardiac Screening Innovation CTScreen v1.5 to Advance High-Throughput, Automated Human-Based Drug Testing

Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology

Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection Fraction

Medera Inc. to be Listed on NASDAQ Through a Merger Agreement with Keen Vision Acquisition Corporation

Medera’s Novoheart Expands Human Cardiac Research with CTScreen™ Installation at University Medical Center, Utrecht

Medera’s Novoheart and Curi Bio Partner to Transform Human-Based Cardiac Drug Screening

Medera’s Novoheart Releases Latest Cardiac Screening Innovation CTScreen v1.5 to Advance High-Throughput, Automated Human-Based Drug Testing

Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology

Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection Fraction

Medera Inc. to be Listed on NASDAQ Through a Merger Agreement with Keen Vision Acquisition Corporation

KVAC - Frequently Asked Questions (FAQ)

Beweger

KVAC Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Keen Vision Acquisition Corporation (KVAC) Börsenkurse

Keen Vision Acquisition Corporation (KVAC)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Über Keen Vision Acquisition Corporation

KVAC Neueste Nachrichten

Medera’s Novoheart Expands Human Cardiac Research with CTScreen™ Installation at University Medical Center, Utrecht

Medera’s Novoheart and Curi Bio Partner to Transform Human-Based Cardiac Drug Screening

Medera’s Novoheart Releases Latest Cardiac Screening Innovation CTScreen v1.5 to Advance High-Throughput, Automated Human-Based Drug Testing

Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology

Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection Fraction

Medera Inc. to be Listed on NASDAQ Through a Merger Agreement with Keen Vision Acquisition Corporation

Medera’s Novoheart Expands Human Cardiac Research with CTScreen™ Installation at University Medical Center, Utrecht

Medera’s Novoheart and Curi Bio Partner to Transform Human-Based Cardiac Drug Screening

Medera’s Novoheart Releases Latest Cardiac Screening Innovation CTScreen v1.5 to Advance High-Throughput, Automated Human-Based Drug Testing

Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology

Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection Fraction

Medera Inc. to be Listed on NASDAQ Through a Merger Agreement with Keen Vision Acquisition Corporation

KVAC - Frequently Asked Questions (FAQ)

Beweger

KVAC Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen